OriGene Antibodies in recent publications
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial British Journal of Cancer 109, 2096-2105 (15 October 2013)
Recruitment of TLR adapter TRIF to TLR4 signaling complex is mediated by the second helical region of TRIF TIR domain PNAS, vol. 110 no. 47: 19036–19041
FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer Cancer Res. 2013 Sep 1;73(17):5416-25
Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions.
Cancer Prevention Research, Jul 2013; 6: 666 - 674.
|View All Citations >>||
Home Gene of the month HES1|
HES1 – Transcriptional Regulator
HES1, hairy and enhancer of split 1, belongs to the basic helix-loop-helix family of transcription factors. It is a transcriptional repressor of genes that require a bHLH protein for their transcription. HES1 is a key developmental gene that is overexpressed in certain cancers and is a primary target of Notch signaling. Notch and hedgehog pathways, which are frequently upregulated in tumors, lead to elevated HES1 levels. Studies of HES1 would lead to better understanding of the relationship between quiescent and cancer cells.
OriGene offers various antibodies against HES1:
- TA500114 has been validated extensively with IHC staining
|IHC staining of paraffin-embedded endometrium using anti-HES1
OriGene products of HES1:
- ORF clones of human HES1 untagged or tagged with Myc-DDK/GFP
- shRNA and siRNA to knockdown HES1 expression
- HES1 protein purified from human cell line
- L.Sang, et. al. Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med. (2010) Jan;16(1):17-26.
View all HES1 products offering from OriGene >>